ATRA
Atara Biotherapeutics, Inc. NASDAQ Listed Oct 16, 2014$9.93
Mkt Cap $84.5M
52w Low $3.92
39.5% of range
52w High $19.14
50d MA $5.15
200d MA $10.29
P/E (TTM)
1.9x
EV/EBITDA
5.4x
P/B
—
Debt/Equity
-1.4x
ROE
-84.9%
P/FCF
-4.5x
RSI (14)
—
ATR (14)
—
Beta
-0.33
50d MA
$5.15
200d MA
$10.29
Avg Volume
231.6K
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
611 Gateway Boulevard · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 16, 2026 | AMC | -0.09 | -0.25 | -177.8% | 5.87 | -2.2% | -10.9% | -14.8% | -12.8% | -16.4% | -17.4% | — |
| Nov 12, 2025 | AMC | -0.83 | -0.32 | +61.4% | 12.47 | -0.2% | +7.4% | +10.3% | +5.1% | +7.9% | +10.2% | — |
| Aug 11, 2025 | AMC | -0.32 | 0.19 | +159.4% | 10.32 | +6.7% | +11.8% | +17.5% | +13.6% | +19.1% | +11.2% | — |
| May 15, 2025 | AMC | -3.07 | 3.50 | +214.0% | 7.61 | -1.4% | -10.1% | -11.6% | -8.0% | -9.3% | -6.6% | — |
| Mar 7, 2025 | AMC | -3.82 | -1.19 | +68.8% | 6.90 | +0.3% | -10.7% | -4.2% | -0.1% | -0.6% | +5.1% | — |
| Nov 12, 2024 | AMC | -3.77 | -2.93 | +22.3% | 11.67 | +2.8% | +22.2% | +9.4% | +2.8% | -2.9% | -5.8% | — |
| Aug 12, 2024 | AMC | -1.25 | -3.10 | -148.0% | 7.77 | +0.4% | +3.2% | -0.6% | -12.1% | -9.8% | -7.5% | — |
| May 9, 2024 | AMC | -9.25 | -5.75 | +37.8% | 13.65 | +4.4% | -2.9% | +1.9% | +10.8% | +17.2% | +10.5% | — |
| Mar 28, 2024 | AMC | -15.25 | -14.00 | +8.2% | 17.35 | +2.8% | +4.5% | +4.8% | +3.7% | +12.2% | +11.5% | — |
| Nov 1, 2023 | AMC | -15.75 | -16.50 | -4.8% | 31.50 | +4.8% | -5.6% | +2.4% | +4.8% | +5.6% | -4.0% | — |
| Aug 8, 2023 | AMC | -16.25 | -17.00 | -4.6% | 56.75 | -4.8% | -17.2% | -4.0% | -7.9% | -13.2% | -18.9% | — |
| May 8, 2023 | AMC | -10.00 | -18.00 | -80.0% | 74.25 | -3.7% | -17.8% | -18.2% | -22.6% | -27.9% | -25.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 8 | Canaccord Genuity | Upgrade | Hold → Buy | $13 | — | — | — | — | — | — | — | — |
| Jan 21 | Freedom Broker | Downgrade | Buy → Sell | — | $4.32 | $4.34 | +0.5% | +6.5% | +15.7% | +20.8% | +22.5% | +28.7% |
| Jan 13 | Canaccord Genuity | Downgrade | Buy → Hold | — | $5.88 | $5.95 | +1.2% | -25.7% | -24.0% | -21.4% | -22.8% | -26.5% |
| Dec 19 | Canaccord Genuity | Maintains | Buy → Buy | — | $17.23 | $17.70 | +2.7% | -0.3% | +3.7% | +1.6% | +2.1% | +0.2% |
| Mar 11 | Canaccord Genuity | Maintains | Buy → Buy | — | $6.16 | $6.24 | +1.3% | +7.3% | +11.9% | +11.4% | +17.7% | +16.4% |
| Jan 22 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $6.05 | $5.99 | -1.0% | +13.9% | +14.5% | +35.9% | +21.8% | +38.2% |
| Jan 17 | Canaccord Genuity | Maintains | Buy → Buy | — | $7.83 | $7.52 | -4.0% | -16.1% | -22.7% | -12.0% | -11.5% | +5.0% |
| Nov 13 | Canaccord Genuity | Maintains | Buy → Buy | — | $11.67 | $12.00 | +2.8% | +22.2% | +9.4% | +2.8% | -2.9% | -5.8% |
| Aug 16 | Mizuho | Upgrade | Neutral → Outperform | — | $6.83 | $7.01 | +2.6% | +2.6% | +5.3% | +5.1% | +6.1% | +4.2% |
| Aug 13 | Canaccord Genuity | Maintains | Buy → Buy | — | $7.77 | $7.80 | +0.4% | +3.2% | -0.6% | -12.1% | -9.8% | -7.5% |
| Jul 17 | Goldman Sachs | Maintains | Sell → Sell | — | $12.27 | $12.44 | +1.4% | -1.8% | -14.3% | -10.3% | -17.4% | -15.0% |
| Apr 1 | Stifel | Maintains | Hold → Hold | — | $17.35 | $17.84 | +2.8% | +4.5% | +4.8% | +3.7% | +12.2% | +11.5% |
| Nov 10 | Goldman Sachs | Maintains | Sell → Sell | — | $6.00 | $6.60 | +10.0% | -4.2% | +7.2% | +45.0% | +58.5% | +100.2% |
| Nov 9 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $30.25 | $12.22 | -59.6% | -80.2% | -81.0% | -78.7% | -71.2% | -68.6% |
| Nov 9 | Mizuho | Downgrade | Buy → Neutral | — | $30.25 | $12.22 | -59.6% | -80.2% | -81.0% | -78.7% | -71.2% | -68.6% |
| Nov 9 | Evercore ISI | Downgrade | Outperform → In Line | — | $30.25 | $12.22 | -59.6% | -80.2% | -81.0% | -78.7% | -71.2% | -68.6% |
| Sep 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $40.75 | $41.00 | +0.6% | -3.7% | -6.7% | -6.1% | -9.2% | -8.0% |
| Aug 21 | Citigroup | Maintains | Sell → Sell | — | $37.25 | $37.50 | +0.7% | -5.4% | -2.0% | +1.3% | +0.7% | -4.7% |
| Aug 9 | EF Hutton | Maintains | Buy → Buy | — | $56.75 | $54.00 | -4.8% | -17.2% | -4.0% | -7.9% | -13.2% | -18.9% |
| Jun 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $53.50 | $54.75 | +2.3% | -2.3% | +0.0% | -6.1% | -10.7% | -11.2% |
| Jun 14 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $53.50 | $54.75 | +2.3% | -2.3% | +0.0% | -6.1% | -10.7% | -11.2% |
| May 9 | Canaccord Genuity | Maintains | Buy → Buy | — | $74.25 | $71.50 | -3.7% | -17.8% | -18.2% | -22.6% | -27.9% | -25.9% |
| Feb 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $126.00 | $119.25 | -5.4% | -5.4% | -15.5% | -11.9% | -7.9% | -10.1% |
| Aug 31 | Goldman Sachs | Maintains | Sell → Sell | — | $99.00 | $100.25 | +1.3% | +1.3% | +9.8% | +8.3% | +6.8% | +14.9% |
| Aug 16 | Mizuho | Maintains | Buy → Buy | — | $133.50 | $132.75 | -0.6% | -7.5% | -11.6% | -11.2% | -16.7% | -21.7% |
| Aug 9 | Goldman Sachs | Maintains | Sell → Sell | — | $90.75 | $96.25 | +6.1% | +29.2% | +36.4% | +28.1% | +60.9% | +47.1% |
| Jul 20 | Citigroup | Downgrade | Neutral → Sell | — | $91.00 | $86.25 | -5.2% | +2.5% | -1.6% | -11.5% | -12.9% | -13.5% |
| Jul 13 | Stifel | Downgrade | Buy → Hold | — | $216.50 | $103.75 | -52.1% | -55.1% | -54.4% | -55.5% | -56.7% | -58.0% |
| Jul 13 | JP Morgan | Downgrade | Overweight → Neutral | — | $216.50 | $103.75 | -52.1% | -55.1% | -54.4% | -55.5% | -56.7% | -58.0% |
| May 24 | Goldman Sachs | Maintains | Sell → Sell | — | $124.50 | $121.25 | -2.6% | -5.8% | -2.8% | -2.2% | +4.6% | +4.4% |
| May 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $129.00 | $131.25 | +1.7% | -3.5% | -9.1% | -6.2% | -5.6% | +1.0% |
| May 10 | Citigroup | Downgrade | Buy → Neutral | — | $143.00 | $149.50 | +4.5% | -0.5% | -12.6% | -8.7% | -4.2% | -7.3% |
| Mar 28 | JP Morgan | Maintains | Overweight → Overweight | — | $235.00 | $236.25 | +0.5% | -0.4% | +3.4% | -2.3% | -1.2% | +1.1% |
| Jan 3 | JP Morgan | Maintains | Overweight → Overweight | — | $394.00 | $400.25 | +1.6% | +7.2% | +3.2% | -1.1% | +1.4% | -0.3% |
| May 13 | JP Morgan | Upgrade | Neutral → Overweight | — | $345.75 | $370.25 | +7.1% | +6.4% | +8.4% | +3.9% | +5.1% | +1.5% |
| May 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $341.25 | $345.75 | +1.3% | -1.1% | -5.6% | -0.4% | -3.0% | +1.9% |
| Dec 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $655.75 | $632.00 | -3.6% | -1.6% | -12.0% | -8.4% | -8.0% | -10.5% |
| Nov 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $360.00 | $373.75 | +3.8% | +8.2% | +9.3% | +25.8% | +25.3% | +35.6% |
| Sep 15 | Canaccord Genuity | Maintains | Buy → Buy | — | $375.75 | $394.25 | +4.9% | +4.1% | +4.4% | +5.1% | +5.6% | -1.3% |
| Aug 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $317.75 | $330.00 | +3.9% | -1.3% | +0.2% | +0.3% | -3.1% | -3.2% |
| Aug 6 | Stifel | Maintains | Buy → Buy | — | $317.75 | $330.00 | +3.9% | -1.3% | +0.2% | +0.3% | -3.1% | -3.2% |
| May 12 | JP Morgan | Maintains | Neutral → Neutral | — | $256.25 | $263.25 | +2.7% | +4.4% | +1.1% | -6.5% | +5.0% | +8.3% |
| Apr 23 | Citigroup | Upgrade | Neutral → Buy | — | $204.75 | $222.00 | +8.4% | +4.5% | +8.2% | +9.5% | +6.3% | +4.2% |
| Nov 8 | JP Morgan | Downgrade | Overweight → Neutral | — | $338.00 | $315.75 | -6.6% | -0.9% | -3.5% | -3.8% | -3.1% | -2.3% |
| Sep 27 | Goldman Sachs | Downgrade | Neutral → Sell | — | $339.50 | $296.25 | -12.7% | -0.9% | +4.0% | -2.5% | +1.2% | +2.1% |
| Sep 16 | Jefferies | Downgrade | Buy → Hold | — | $379.00 | $360.00 | -5.0% | -1.1% | +3.2% | +0.5% | +0.5% | +4.3% |
| Jun 4 | Citigroup | Upgrade | Sell → Neutral | — | $583.00 | $599.00 | +2.7% | +3.7% | -0.6% | -3.1% | -5.3% | -4.2% |
| Jun 11 | Citigroup | Maintains | Sell → Sell | — | $1125.00 | $1120.00 | -0.4% | -4.8% | -2.3% | +0.2% | +1.4% | +0.1% |
| Feb 28 | JMP Securities | Downgrade | Market Outperform → Market Perform | — | $1063.75 | $982.50 | -7.6% | -9.5% | -12.6% | -7.4% | +0.9% | +2.1% |
| Feb 15 | Citigroup | Downgrade | Neutral → Sell | — | $1208.75 | $1071.25 | -11.4% | -2.7% | -6.1% | -7.3% | -9.7% | -11.3% |
No insider trades available.
8-K · 8.01
!! High
Atara Biotherapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Atara Biotherapeutics received an FDA Complete Response Letter for EBVALLO, indicating the agency requires additional data or modifications before approving the cell therapy candidate.
May 7
8-K
Atara Biotherapeutics, Inc. -- 8-K Filing
Atara Biotherapeutics' common stock will continue trading on Nasdaq Global Select Market under ticker ATRA with no change to its listing status.
May 1
8-K
Unknown — 8-K Filing
Atara Biotherapeutics is cutting costs to extend runway while advancing its EBV T-cell platform, suggesting management expects a longer path to profitability but remains committed to development.
Mar 16
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Atara Biotech's tabelecleucel faces FDA regulatory hurdles requiring a Type A meeting to address deficiencies, potentially delaying commercialization and revenue generation for this key cancer immunotherapy candidate.
Mar 12
8-K · 8.01
!! High
Atara Biotherapeutics, Inc -- 8-K 8.01: Material Event / Announcement
Atara Biotherapeutics is seeking an FDA meeting to address deficiencies in its EBVALLO therapy application, signaling potential pathway forward for the rejected cancer treatment after initial rejection.
Mar 3
8-K · 8.01
!! High
Atara Biotherapeutics, Inc -- 8-K 8.01: Material Event / Announcement
Atara Biotherapeutics issued a business update on February 23, 2026, likely detailing operational progress, financial performance, or strategic developments relevant to investors evaluating the company's near-term prospects.
Feb 23
Data updated apr 24, 2026 7:41pm
· Source: massive.com